Critical roles of TRAIL in hepatic cell death and hepatic inflammation

Journal of Clinical Investigation

Volumn 113, Issue 1, 2004, Pages 58-64

  Zheng, Shi Jun ^a   Wang, Pu ^a   Tsabary, Galit ^a   Chen, Youhai H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; APOPTOSIS REGULATORY PROTEIN; CONCANAVALIN A; MEMBRANE PROTEIN; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; HEPATITIS; IMMUNOCOMPETENT CELL; LIVER CELL; LIVER CELL DAMAGE; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; ANIMAL HEPATITIS; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; INNATE IMMUNITY; LISTERIOSIS; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CONCANAVALIN A; GENE EXPRESSION REGULATION; HEPATITIS, ANIMAL; IMMUNITY, NATURAL; INFLAMMATION; LISTERIA INFECTIONS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542466794     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200419255     Document Type: Article

References (30)

1. Ksontini, R., et al. 1998. Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis. J. Immunol. 160:4082-4089.
2. Ando, K., et al. 1997. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol. 158:5283-5291.
3. Kondo, T., Suda, T., Fukuyama, H., Adachi, M., and Nagata, S. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3:409-413.
4. Chirmule, N., et al. 1999. Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. Hum. Gene Ther. 10:259-269.
5. Wiley, S.R., et al. 1993. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673-682.
6. Pan, G., et al. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:815-818.
7. Pan, G., et al. 1997 The receptor for the cytotoxic ligand TRAIL. Science. 276:111-113.
8. Walczak, H., et al. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386-5397.
9. Wu, G.S., Burns, T.F., Zhan, Y., Alnemri, E.S., and El-Deiry, W.S. 1999. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59:2770-2775.
10. Schneider, P., et al. 1997. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 7:831-836.
11. Degli-Esposti, M.A., et al. 1997. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:813-820.
12. Sheridan, J.P., et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:818-821.
13. Emery, J.G., et al. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273:14363-14367.
14. Schneider, P., et al. 2002. Identification of a new murine TNF receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Biol. Chem. 3:3.
15. Walczak, H., et al. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157-163.
16. Ashkenazi, A., et al. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:155-162.
17. Jo, M., et al. 2000. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6:564.
18. Cretney, E., et al. 2002. Increased susceptibility to tumor initiation and metastasis in TNF related apoptosis-inducing ligand-deficient mice. J. Immunol. 168:1356-1361.
19. Song, K., et al. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med 191:1095-1104.
20. Bouckson, V., et al. 1994. Characterization of liver lymphomyeloid cells in mice infected with Plasmodium yoelii sporozoites. Immunobiology. 191:413-423.
21. Kaneko, Y., et al. 2000. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A induced hepatitis. J. Exp. Med. 191:105-114.
22. Takeda, K., et al. 2000. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. U. S. A. 97:5498-5503.
23. Taimr, P., et al. 2003. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology. 37:87-95.
24. Gascon-Barre, M., Huet, P.M., Belgiorno, J., Plourde, V., and Coulombe, P.A. 1989. Estimation of collagen content of liver specimens. Variation among animals and among hepatic lobes in cirrhotic rats. J. Histochem. Cytochem. 37:377-381.
25. Song, E., et al. 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9:347-351.
26. Martin-Villalba, A., et al. 1999. CD95 ligand (Fas L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19:3809-3817.
27. Lamharnedi-Cherradi, S.-E., Zheng, S., Maguschak, K., Peschon, J., and Chen, Y.H. 2003. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol. 4:255-260.
28. Mundr, B., et al. 2003. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J. 17:94-96.
29. Ichikawa, K., et al. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7:954-960.
30. Han, L.H., et al. 2002. Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J. Gastroenterol. 8:1077-1080